Immunome, Inc.
665 Stockton Drive
Suite 100
Exton
PA
19341
United States
20 articles with Immunome, Inc.
-
Immunome Appoints Franklyn G. Prendergast, M.D., Ph.D., to Board of Directors
6/17/2021
Immunome, Inc., a biopharmaceutical company that utilizes its human memory B cell discovery engine platform to discover and develop first-in-class antibody therapeutics, announced the appointment of Franklyn G. Prendergast, M.D., Ph.D., to its Board of Directors.
-
Immunome to Present at the Jefferies Virtual Healthcare Conference
5/27/2021
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell discovery engine platform to discover and develop first-in-class antibody therapeutics, today announced that Purnanand Sarma, Ph.D., President and CEO of Immunome, will present at the Jefferies Virtual Healthcare Conference on Friday, June 4, 2021, at 8:00 a.m. ET.
-
Immunome Announces Additional $4.3 Million Award by DOD following Positive Preclinical Testing Results on COVID-19 Variants of Concern
5/20/2021
Immunome, Inc today announced a $4.3 million increase awarded by the U.S. Department of Defense’s (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense
-
Immunome Reports First Quarter 2021 Financial Results
5/12/2021
IMM-BCP-01: Selected antibody cocktail demonstrating neutralization of CDC SARS-CoV-2 “variants of concern” in preclinical testing, progressing towards IND filing
-
Immunome Announces $27 Million Private Placement
4/26/2021
Immunome, Inc. announced it has entered into a definitive securities purchase agreement for the sale of its equity securities in a private placement with certain accredited investors for gross proceeds to Immunome of approximately $27 million, before deducting placement agent commissions and other offering expenses.
-
Immunome SARS-CoV-2 Antibody Cocktail Neutralizes UK, South Africa, Brazil and California Variants in Preclinical Testing; Progressing Towards IND Filing
4/26/2021
Antibody cocktail (IMM-BCP-01) is a combination of three antibodies that bind to complementary, non-overlapping regions of the SARS-CoV-2 spike protein.
-
Immunome Appoints Dr. Dennis Giesing as Chief Development Officer
3/30/2021
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell discovery engine platform to discover and develop first-in-class antibody therapeutics, today announced the appointment of Dennis Giesing, Ph.D., to the role of Chief Development Officer (CDO). In this position,
-
Immunome Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update
3/25/2021
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell discovery engine platform to discover and develop first-in-class antibody therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a corporate update.
-
Immunome Advances Its Proprietary Antibody Against IL-38, a Novel Innate Immune Checkpoint, into IND-enabling Studies
3/23/2021
First oncology product candidate identified using the company’s human memory B-cell platform, and intended for potential treatment of solid tumors
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 23, 2021.
-
Immunome Discovers Antibodies Capable of Neutralizing Multiple SARS-CoV-2 Variants, Including the South African Variant, in Pseudovirus Testing
2/18/2021
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics, announced today that its discovery engine has isolated potent antibodies capable of neutralizing several SARS-CoV-2 variants, including the South African Variant (B.1.351), in pseudovirus testing.
-
Shares in the company shot up 212.6% following the news it had isolated the potentially variant-neutralizing antibodies.
-
Abzena Selected by Immunome to Develop and Manufacture Antibody Cocktail for Immunome’s COVID-19 Antibody Based Treatment
2/3/2021
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics, and Abzena, a partner research organization for integrated discovery to cGMP manufacturing solutions for biologics, today announced that Abzena was selected as Immunome’s partner research organization for IMM-BCP-01,
-
Immunome’s Research Reveals a Broad Super Responder Memory B Cell Response to the SARS-CoV-2 Virus
2/1/2021
Findings support the potential of Immunome’s approach to developing IMM-BCP-01 as an optimized antibody cocktail for the treatment and prophylaxis of COVID-19
-
Immunome Reports Third Quarter 2020 Financial Results and Significant Progress
11/17/2020
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics, with a focus on oncology and infectious diseases including COVID-19, today announced third quarter 2020 financial results and recent highlights.
-
Immunome Announces Exercise in Full and Closing of Over-Allotment Option in Initial Public Offering
10/13/2020
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics, with a focus on oncology and infectious diseases, including COVID-19, today announced the full exercise of the underwriters' option to purchase an additional 487,500 shares of common stock at the public offering price of $12.00 per share, resulting in add
-
Immunome Announces Pricing of Upsized Initial Public Offering
10/2/2020
Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated, today announced the pricing of its initial public offering.
-
BioSpace Movers & Shakers, Sept. 18
9/18/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Immunome Announces Creation of COVID-19 Advisory Board
9/16/2020
Advisory Board to help guide development and clinical testing of biosynthetic convalescent plasma as a potential COVID-19 treatment and prevention of disease
-
Immunome Awarded Department of Defense Contract to Develop Biosynthetic Convalescent Plasma for COVID-19
7/28/2020
Up to $13.3M funding to accelerate development and early clinical testing of antibodies derived from large-scale B cell interrogation of COVID-19 “Super-Responders”